Das Dhriti Sundar, Anupam Anurag, Saharia Gautom Kumar
Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Department of Biochemistry, AIIMS Bhubaneswar, Bhubaneswar, India.
Front Med (Lausanne). 2024 Aug 20;11:1387472. doi: 10.3389/fmed.2024.1387472. eCollection 2024.
In resource-constrained countries, inadequate access to healthcare and prognostic tools can be the Achilles' heel in effectively managing chronic kidney disease (CKD). There is a significant similarity in the pathogenesis of CKD and liver fibrosis. The role of liver fibrosis (LF) scores in predicting short-term clinical outcomes in hospitalized patients with CKD is unknown. Our study aimed at calculating LF scores and studying the association of liver fibrosis with short-term mortality and morbidity in CKD patients.
Patients aged above 15 years diagnosed with CKD as per the KDIGO criteria were enrolled. LF scores, namely, NFS, GPRI, and FIB-4 scores were calculated. Patients were followed up for a period of 28 days for good and poor composite outcomes, namely, the requirement of hemodialysis, non-invasive ventilation, prolonged hospital stay, and neurological and cardiovascular outcomes including death.
Among 163 patients, 70.5% were below 60 years of age, 82.2% were male and 35% were diabetic. At 28-day follow up, 52.1% had poor composite outcome. The AUROC for GPRI and FIB-4 in predicting poor outcomes was 0.783 (95% CI: 0.71-0.855) ( < 0.001) and 0.62 (95% CI: 0.534-0.706) ( = 0.008), respectively. The AUROC for GPRI and NFS in predicting all-cause mortality was 0.735 (95% CI: 0.627-0.843) ( = 0.001) and 0.876 (95% CI, 0.8-0.952) ( < 0.001), respectively.
We found a positive association between LF scores and CKD outcomes in hospitalized patients. The LF scores significantly predicted poor outcomes in patients with CKD. Among the scores, GPRI was found to be a stronger predictor in predicting outcomes in both diabetic and non-diabetic patients with CKD. A high GPRI score was also associated with poor outcomes and increased mortality in both diabetics and non-diabetics.
在资源有限的国家,获得医疗保健和预后工具的机会不足可能是有效管理慢性肾脏病(CKD)的致命弱点。CKD的发病机制与肝纤维化有显著相似之处。肝纤维化(LF)评分在预测CKD住院患者短期临床结局中的作用尚不清楚。我们的研究旨在计算LF评分,并研究肝纤维化与CKD患者短期死亡率和发病率之间的关联。
纳入根据KDIGO标准诊断为CKD的15岁以上患者。计算LF评分,即NFS、GPRI和FIB-4评分。对患者进行为期28天的随访,观察良好和不良复合结局,即血液透析需求、无创通气、住院时间延长以及包括死亡在内的神经和心血管结局。
163例患者中,70.5%年龄在60岁以下,82.2%为男性,35%患有糖尿病。在28天的随访中,52.1%的患者有不良复合结局。GPRI和FIB-4预测不良结局的受试者工作特征曲线下面积(AUROC)分别为0.783(95%CI:0.71-0.855)(P<0.001)和0.62(95%CI:0.534-0.706)(P=0.008)。GPRI和NFS预测全因死亡率的AUROC分别为0.735(95%CI:0.627-0.843)(P=0.001)和0.876(95%CI,0.8-0.952)(P<0.001)。
我们发现住院患者的LF评分与CKD结局之间存在正相关。LF评分显著预测了CKD患者的不良结局。在这些评分中,GPRI被发现是预测CKD糖尿病和非糖尿病患者结局的更强指标。高GPRI评分也与糖尿病和非糖尿病患者的不良结局及死亡率增加相关。